AU2017359023B2 - 3-substituted propionic acids as alpha v integrin inhibitors - Google Patents

3-substituted propionic acids as alpha v integrin inhibitors Download PDF

Info

Publication number
AU2017359023B2
AU2017359023B2 AU2017359023A AU2017359023A AU2017359023B2 AU 2017359023 B2 AU2017359023 B2 AU 2017359023B2 AU 2017359023 A AU2017359023 A AU 2017359023A AU 2017359023 A AU2017359023 A AU 2017359023A AU 2017359023 B2 AU2017359023 B2 AU 2017359023B2
Authority
AU
Australia
Prior art keywords
tetrahydro
naphthyridin
propanoic acid
propyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017359023A
Other languages
English (en)
Other versions
AU2017359023A1 (en
Inventor
Palanikumar BALASUBRAMANIAN
Rita Civiello
Pratik Devasthale
Suresh Dhanusu
Leatte R. GUERNON
Xiaojun Han
Swanee E. Jacutin-Porte
Michael F. Parker
Kumaravel Selvakumar
Xiang-Yang Ye
Guohua Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2017359023A1 publication Critical patent/AU2017359023A1/en
Application granted granted Critical
Publication of AU2017359023B2 publication Critical patent/AU2017359023B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017359023A 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors Active AU2017359023B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662418848P 2016-11-08 2016-11-08
US62/418,848 2016-11-08
PCT/US2017/060376 WO2018089353A1 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Publications (2)

Publication Number Publication Date
AU2017359023A1 AU2017359023A1 (en) 2019-06-20
AU2017359023B2 true AU2017359023B2 (en) 2021-12-09

Family

ID=60409432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017359023A Active AU2017359023B2 (en) 2016-11-08 2017-11-07 3-substituted propionic acids as alpha v integrin inhibitors

Country Status (30)

Country Link
US (2) US10968219B2 (OSRAM)
EP (1) EP3538525B1 (OSRAM)
JP (1) JP7097358B2 (OSRAM)
KR (1) KR102505629B1 (OSRAM)
CN (1) CN110167935B (OSRAM)
AR (1) AR110153A1 (OSRAM)
AU (1) AU2017359023B2 (OSRAM)
CA (1) CA3042707A1 (OSRAM)
CL (1) CL2019001264A1 (OSRAM)
CO (1) CO2019005824A2 (OSRAM)
DK (1) DK3538525T3 (OSRAM)
EA (1) EA038164B1 (OSRAM)
ES (1) ES2925173T3 (OSRAM)
HR (1) HRP20220990T1 (OSRAM)
HU (1) HUE059708T2 (OSRAM)
IL (1) IL266473B (OSRAM)
LT (1) LT3538525T (OSRAM)
MA (1) MA46743A (OSRAM)
MX (1) MX380799B (OSRAM)
MY (1) MY199931A (OSRAM)
NZ (1) NZ754207A (OSRAM)
PE (1) PE20191647A1 (OSRAM)
PL (1) PL3538525T3 (OSRAM)
PT (1) PT3538525T (OSRAM)
RS (1) RS63483B1 (OSRAM)
SI (1) SI3538525T1 (OSRAM)
SM (1) SMT202200338T1 (OSRAM)
TW (1) TWI763733B (OSRAM)
WO (1) WO2018089353A1 (OSRAM)
ZA (1) ZA201903665B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049068A1 (en) 2016-09-07 2018-03-15 Pliant Therapeutics, Inc. N-acyl amino acid compounds and methods of use
ES2925173T3 (es) * 2016-11-08 2022-10-14 Bristol Myers Squibb Co Acidos propiónicos sustituidos en la posición 3 como inhibidores de la integrina alfa V
BR112019009245A2 (pt) * 2016-11-08 2019-07-16 Bristol-Myers Squibb Company azol amidas e aminas como inibidores de alfav integrina
EP3538526B1 (en) * 2016-11-08 2024-04-10 Bristol-Myers Squibb Company Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors
RU2019116820A (ru) 2016-12-29 2021-01-29 Сент-Луис Юниверсити Антагонисты интегрина
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
BR112019017929A2 (pt) 2017-02-28 2020-05-19 Morphic Therapeutic Inc inibidores de integrina (alfa-v)(beta-6)
ES3019404T3 (en) 2018-08-29 2025-05-20 Morphic Therapeutic Inc Integrin inhibitors
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
WO2020092375A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
ES3013256T3 (en) 2018-10-30 2025-04-11 Gilead Sciences Inc Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
CN112996786B (zh) 2018-10-30 2024-08-20 吉利德科学公司 用于抑制α4β7整合素的化合物
CN109824495B (zh) * 2019-02-02 2022-12-09 盐城师范学院 一种新型偶联反应在制备碳-碳键结构化合物中的应用
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound
WO2025064802A1 (en) * 2023-09-21 2025-03-27 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α5β1

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6090944A (en) * 1998-08-13 2000-07-18 Merck & Co., Inc. Alkanoic acid derivatives as αv integrin receptor antagonists
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US20080255183A1 (en) * 2007-04-11 2008-10-16 Astrazeneca Ab N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
US20160264566A1 (en) * 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451790A1 (de) * 1990-04-12 1991-10-16 Hoechst Aktiengesellschaft 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en) 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
JP2001524481A (ja) 1997-11-26 2001-12-04 デュポン ファーマシューティカルズ カンパニー αＶβ３アンタゴニストとしての１，３，４−チアジアゾール類および１，３，４−オキサジアゾール類
AU2002243692B2 (en) 2001-01-29 2006-06-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
JP2006513218A (ja) * 2002-12-20 2006-04-20 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのピラゾール化合物
EP1592421A1 (en) * 2002-12-20 2005-11-09 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
WO2006108040A1 (en) 2005-04-05 2006-10-12 Janssen Pharmaceutica, N.V. Substituted indoles and their use as integrin antagonists
TW200800999A (en) * 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
CN102482225B (zh) 2009-09-04 2016-10-05 巴斯夫欧洲公司 制备1-苯基吡唑类的方法
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
ITFI20100019A1 (it) 2010-02-12 2011-08-13 Univ Firenze Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3925959A1 (en) 2015-02-19 2021-12-22 OcuTerra Therapeutics, Inc. Fluorinated derivatives of 3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid and uses thereof
ES2925173T3 (es) * 2016-11-08 2022-10-14 Bristol Myers Squibb Co Acidos propiónicos sustituidos en la posición 3 como inhibidores de la integrina alfa V

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999030709A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
US6090944A (en) * 1998-08-13 2000-07-18 Merck & Co., Inc. Alkanoic acid derivatives as αv integrin receptor antagonists
US20080045521A1 (en) * 2006-06-09 2008-02-21 Astrazeneca Ab Phenylalanine derivatives
US20080255183A1 (en) * 2007-04-11 2008-10-16 Astrazeneca Ab N-[HETEROARYLCARBONYL]-3-THIENYL-L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS
US20160264566A1 (en) * 2015-03-10 2016-09-15 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use

Also Published As

Publication number Publication date
TWI763733B (zh) 2022-05-11
US20210188847A1 (en) 2021-06-24
KR20190073554A (ko) 2019-06-26
TW201823244A (zh) 2018-07-01
EA038164B1 (ru) 2021-07-16
EA201991122A1 (ru) 2019-10-31
MA46743A (fr) 2019-09-18
CN110167935B (zh) 2022-05-27
AR110153A1 (es) 2019-02-27
CL2019001264A1 (es) 2019-09-13
AU2017359023A1 (en) 2019-06-20
NZ754207A (en) 2025-09-26
IL266473B (en) 2022-06-01
LT3538525T (lt) 2022-09-26
MX380799B (es) 2025-03-12
MY199931A (en) 2023-11-29
RS63483B1 (sr) 2022-09-30
JP7097358B2 (ja) 2022-07-07
WO2018089353A1 (en) 2018-05-17
US10968219B2 (en) 2021-04-06
MX2019005244A (es) 2019-08-05
ZA201903665B (en) 2022-12-21
EP3538525A1 (en) 2019-09-18
ES2925173T3 (es) 2022-10-14
US11884661B2 (en) 2024-01-30
JP2019537594A (ja) 2019-12-26
SMT202200338T1 (it) 2022-09-14
KR102505629B1 (ko) 2023-03-02
DK3538525T3 (da) 2022-08-29
US20190263808A1 (en) 2019-08-29
HRP20220990T1 (hr) 2022-11-11
CO2019005824A2 (es) 2019-06-11
CA3042707A1 (en) 2018-05-17
IL266473A (en) 2019-07-31
HUE059708T2 (hu) 2022-12-28
PE20191647A1 (es) 2019-11-07
CN110167935A (zh) 2019-08-23
EP3538525B1 (en) 2022-06-22
PT3538525T (pt) 2022-08-16
PL3538525T3 (pl) 2022-09-12
SI3538525T1 (sl) 2022-09-30

Similar Documents

Publication Publication Date Title
AU2017359023B2 (en) 3-substituted propionic acids as alpha v integrin inhibitors
JP7268116B2 (ja) Ｒｏｃｋ阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物
CN107406426B (zh) 作为rock抑制剂的环状脲类
CN105073741B (zh) 作为rock抑制剂的酞嗪酮及异喹啉酮
CN107108581B (zh) 作为强效rock抑制剂的回接苯甲酰胺衍生物
EP3538519B1 (en) Indazole derivatives as alpha v integrin antagonists
ES2898835T3 (es) Azol amidas y aminas como inhibidores de la integrina alfav
CA3042710A1 (en) Cyclobutane- and azetidine-containing mono and spirocyclic compounds as .alpha.v integrin inhibitors
AU2017359030A1 (en) Pyrrole amides as alpha v integrin inhibitors
US11286252B2 (en) Alkene spirocyclic compounds as farnesoid X receptor modulators
HK40009959B (en) 3-substituted propionic acids as alpha v integrin inhibitors
HK40009959A (en) 3-substituted propionic acids as alpha v integrin inhibitors
BR112019009199B1 (pt) Compostos de ácidos propiônicos 3-substituídos, composição farmacêutica e seus usos como inibidores de alfa v integrina

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)